Description: Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-' agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
Home Page: www.madrigalpharma.com
MDGL Technical Analysis
Four Tower Bridge
West Conshohocken,
PA
19428
United States
Phone:
267 824 2827
Officers
| Name | Title |
|---|---|
| Dr. Paul A. Friedman M.D. | Chairman & CEO |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, Pres of R&D and Director |
| Mr. Alex G. Howarth | Sr. VP & CFO |
| Mr. Brian J. Lynch J.D. | Sr. VP & Gen. Counsel |
| Mr. Remy Sukhija | Sr. VP & Chief Commercial Officer |
| Dr. Kianoush Motesharei Ph.d. | Sr. VP of Bus. & Corp. Devel. |
| Mr. Edward Chiang | Sr. VP of Clinical & Technical Operations |
| Mr. Thomas W. Hare | Sr. VP of Clinical Management |
| Dr. Robert E. Waltermire Ph.D. | Chief Pharmaceutical Devel. Officer |
| Dr. Stephen Dodge M.B.A., Pharm.D. | Sr. VP of Global Medical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 93.5958 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2007-02-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 71 |